NAFLD, NASH and Orthotopic Liver Transplantation

Fatty Liver Disease: NASH and Related Disorders

Volumn , Issue , 2007, Pages 208-217

  Burke, Anne ^a   Lucey, Michael R ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Cryptogenic cirrhosis; Hepatic steatosis; Hypertension; Liver transplantation; Obesity

Indexed keywords

EID: 84882478708     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987438.ch17     Document Type: Chapter

References (72)

1. Liver transplant waiting list. UNOS database, 2000.
2. Todo S, DeMetris AJ, Makowka L et al. Primary nonfunction of hepatic allografts with pre-existing fatty infiltration. Transplantation 1989; 47: 903-5.
3. Hilden M, Christoffersen P, Juhl E, Dalgaard JB. Liver histology in a 'normal' population: examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 1977; 12: 593-7.
4. Ostrom M, Eriksson A. Single-vehicle crashes and alcohol: a retrospective study of passenger car fatalities in northern Sweden. Accid Anal Prev 1993; 25: 171-6.
5. Imber CJ, St Peter SD, Lopez I, Guiver L, Friend PJ. Current practice regarding the use of fatty livers: a transAtlantic survey. Liver Transpl 2002; 8: 545-9.
6. Marsman WA, Wiesner RH, Rodriguez L et al. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 1996; 62: 1246-51.
7. Verran D, Kusyk T, Painter D et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl 2003; 9: 500-5.
8. Fishbein TM, Fiel IM, Emre S et al. Use of livers with microvesicular fat safely expands the donor pool. Trans-plantation 1997; 64: 248-51.
9. Urena MA, Moreno GE, Romero CJ, Ruiz-Delgado FC, Moreno SC. An approach to the rational use of steatotic donor livers in liver transplantation [Review]. Hepato-gastroenterology 1999; 46: 1164-73.
10. Imber CJ, St Peter SD, Handa A, Friend PJ. Hepatic steatosis and its relationship to transplantation. Liver Transpl 2002; 8: 415-23.
11. Cortez-Pinto H, Lin HZ, Yang SQ, Da Costa SO, Diehl AM. Lipids upregulate uncoupling protein 2 expression in rat hepatocytes. Gastroenterology 1999; 116: 1184-93.
12. Cisneros C, Guillen F, Gomez R et al. Analysis of warm ischaemia time for prediction of primary non-function of the hepatic graft. Transplant Proc 1991; 23: 1976.
13. Fukumori T, Ohkohchi N, Tsukamoto S, Satomi S. The mechanisms of injury in a steatotic liver graft during cold preservation. Transplantation 1999; 67: 195-200.
14. Seki S, Kitada T, Yamada T et al. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002; 37: 56-62.
15. Soltyl K, Dikdan G, Koneru B. Oxidative stress in fatty livers of obese Zucker rats: rapid amelioration and improved tolerance to warm ischemia with tocopherol. Hepatology 2003; 34: 13-8.
16. Brown RS, Russo MW, Lai M et al. A survey of liver transplantation from living adult donors in the United States. N Engl J Med 2003; 348: 818-25.
17. Rinella ME, Alonso E, Rao S et al. Body mass index as a predictor of hepatitic steatosis in living liver donors. Liver Transpl 2001; 7: 409-14.
18. Trotter JF. Thin chance for fat people to become living donors. Liver Transpl 2001; 7: 415-7.
19. Siegelman I, Rosen MA. Imaging of hepatic steatosis. Semin Liver Dis 2001; 21: 71.
20. Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002; 97: 2408-14.
21. Raynard B, Balian A, Falik D et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002; 35: 635-58.
22. Naveau S, Giraud V, Borotto E et al. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25: 108-11.
23. Nair SP, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002; 35: 105-9.
24. Charlton M, Kasparova P, Weston S et al. Frequency of non-alcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001; 7: 608-14.
25. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000; 32: 689-92.
26. Caldwell SH, Oelsner DH, Iezzoni JC et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-9.
27. National Diabetes Fact Sheet, 2002. Centers for Disease Control, 2002.
28. Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Hepatology 1999; 116: 1413-9.
29. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-10.
30. Sheth SG, Gordon FD, Chopra S. Non-alcoholic steatohepatitis. Ann Intern Med 1997; 126: 137-45.
31. Propst A, Propst T, Judmaier G, Vogel W. Prognosis in non-alcoholic steatohepatitis. Gastroenterology 1995; 108: 1607.
32. Angulo P, Keach JC, Batts K, Lindor KD. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
33. Shields PL, Tang H, Neuberger JM et al. Poor outcome in patients with diabetes mellitus undergoing liver trans-plantation. Transplantation 1999; 68: 530-5.
34. Contos MJ, Cales W, Sterling RK et al. Development of non-alcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001; 7: 363-73.
35. Sawyer RG, Pelletier SJ, Pruett TL. Increased early morbidity and mortality with acceptable long-term function in severely obese patients undergoing liver transplantation. Clin Transplant 1999; 13 (part 2): 126-40.
36. Lucey MR, Browne KA, Everson GT et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transplant Surg 1997; 3: 628-37.
37. Morris CK, Ueshima K, Kawaguchi T et al. The prognostic value of exercise capacity: a review of the literature. Am Heart J 1991; 122: 1423-31.
38. Colle IO, Moreau R, Godinho E et al. Diagnosis for portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003; 37: 401-9.
39. Ramsay MAE, Simpson BR, Nguyen A-T et al. Severe pulmonary hypertension in liver transplant candidates. Liver Transplant Surg 1997; 3: 494-500.
40. Krowka MJ, Plevak DJ, Findlay JY et al. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000; 6: 443-50.
41. Ray CS, Sue DY, Bray G, Hansen JE, Wasserman K. Effects of obesity on respiratory function. Am Rev Respir Dis 1983; 128: 501-6.
42. Marik P, Varon J. The obese patient in the ICU. Chest 1998; 113: 492-8.
43. Rose DK, Cohen MM, Wigglesworth DF, DeBoer DP. Critical respiratory events in the post-anesthesia care unit: patient, surgical and anesthetic factors. Anesthesiology 1994; 81: 410-8.
44. Cauble MS, Gilroy R, Sorrell MF et al. Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation. Transplantation 2001; 71: 892-5.
45. Duchini A, Brunson ME. Rous-en-Y gastric bypass for recurrent non-alcoholic steatohepatitis in liver transplant recipients with morbid obesity. Transplantation 2001; 72: 156-71.
46. Garcia RF, Morales E, Garcia CE et al. Recurrent and de novo non-alcoholic steatohepatitis following orthotopic liver transplantation. Arq Gastroenterol 2001; 38: 247-53.
47. Molloy RM, Komorowski R, Varma RR. Recurrent non-alcoholic steatohepatitis and cirrhosis after liver transplantation. Liver Transplant Surg 1997; 3: 117-78.
48. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomized controlled trial. Lancet 2002; 360: 1119-25.
49. Guckelberger O, Langrehr JM, Bechstein WO et al. Does the choice of primary immunosuppression influence the prevalence of cardiovascular risk factors after liver transplantation. Transplant Proc 1996; 28: 3173-4.
50. Ali A, Befeler AS, Bacon BR et al. Hyperhomocysteinemia in liver transplant recipients [Abstract]. Transplantation 2000; 68 (Suppl.): S391.
51. Canzanello VJ, Schwartz L, Taler SJ et al. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporin A and tacrolimus (FK506). Liver Transplant Surg 1997; 3: 1-9.
52. Monsour HP, Wood RP, Dyer CH et al. Renal insufficiency and hypertension as long-term complications in liver transplantation. Semin Liver Dis 1995; 15: 123-32.
53. Bismuth M, Pageaux G-P, Onea D et al. Follow-up of patients surviving more than 5 years after liver transplantation [Abstract]. Hepatology 2000; 32: 255A.
54. Sanchez EQ, Marubashi S, Jung GJ et al. De novo tumours after liver transplantation occur in a set timeline [Abstract]. Transplantation 2000; 69: S392.
55. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15-36.
56. Jones CA, McQuillan GM, Kusek JW et al. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998; 32: 992-9.
57. Burke A. Medical management of the liver transplant patient. In: Lucey MR, Shaked A, Neuberger JM, eds. Liver Transplantation. Texas: Landes Bioscience, 2003.
58. Painter P, Krasnoff J, Paul SM, Ascher NL. Physical activity and health-related quality of life in liver transplant recipients. Liver Transpl 2001; 7: 213-9.
59. Reaven GM. Importance of identifying the overweight patient who will benefit the most by losing weight. Ann Intern Med 2003; 138: 420-3.
60. Bogardus C, Lillioja S, Mott DM, Hollenbeck C, Reaven GM. Relationship between degree of obesity and in vivo insulin action in man. Am J Physiol 2003; 248 (part 1): E286-91.
61. Day CP, James OFW. Hepatic steatosis: innocent bystander or guilty party. Hepatology 1998; 27: 1463-6.
62. Free radicals, and other reactive species and disease. In: Halliwell B, Gutteridge JMC, eds. Free Radicals in Biology and Medicine. Oxford: Oxford University Press, 1999: 617.
63. Reilly M, Pratico D, Delanty N et al. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation 19298; 98: 2822-8.
64. Burke A, FitzGerald GA, Lucey MR. A prospective analysis of oxidative stress and liver transplantation. Transplantation 2002; 74: 217-21.
65. Mehta SH, Brancati FL, Sulkowski MS et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-9.
66. Monto A. Hepatitis C and steatosis. Semin Gastrointest Dis 2002; 13: 40-6.
67. Fujie H, Yotsuyanagi H, Moriya K et al. Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. J Med Virol 1999; 59: 141-5.
68. Fiore G, Fera G, Vella F, Schiraldi O. Liver steatosis and chronic hepatitis C: a spurious association? Gastroenterol Hepatol 1996; 8: 125-9.
69. Jain SK, Pemberton PW, Smith A et al. Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. J Hepatol 2002; 36: 805-11.
70. Després J-P, Lamarche B. Effects of diet and physical activity on adiposity and body fat distribution: implications for the prevention of cardiovascular disease. Nutr Res Rev 1993; 6: 137-59.
71. Després J-P. Visceral obestiy, insulin resistance, and dyslipidaemia: contribution of endurance exercise training to the treatment of the plurimetabolic syndrome. Exerc Sport Sci Rev 1997; 25: 271-300.
72. Nicholas JJ, Oleske D, Robinson LR, Switala JA, Tarter RE. The quality of life after orthotopic liver transplantation: an analysis of 166 cases. Arch Phys Med Rehabil 1994; 75: 431-7.